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OBJECTIVES The purpose of this study was to evaluate the safety and effectiveness of pacemaker lead
extraction with the excimer sheath in comparison to nonlaser lead extraction.
BACKGROUND Fibrotic attachments that develop between chronically implanted pacemaker leads and to the
venous, valvular and cardiac structures are the major obstacles to safe and consistent lead
extraction. Locking stylets and telescoping sheaths produce a technically demanding but
effective technique of mechanically disrupting the fibrosis. However, ultraviolet excimer laser
light dissolves instead of tearing the tissue attachments.
METHODS A randomized trial of lead extraction was conducted in 301 patients with 465 chronically
implanted pacemaker leads. The laser group patients had the leads removed with identical
tools as the nonlaser group with the exception that the inner telescoping sheath was replaced
with the 12-F excimer laser sheath. Success for both groups was defined as complete lead
removal with the randomized therapy without complications.
RESULTS Complete lead removal rate was 94% in the laser group and 64% in the nonlaser group (p 5
0.001). Failed nonlaser extraction was completed with the laser tools 88% of the time. The
mean time to achieve a successful lead extraction was significantly reduced for patients
randomized to the laser tools, 10.1 6 11.5 min compared with 12.9 6 19.2 min for patients
randomized to nonlaser techniques (p , 0.04). Potentially life-threatening complications
occurred in none of the nonlaser and three of the laser patients, including one death (p 5 NS).
CONCLUSIONS Laser-assisted pacemaker lead extraction has significant clinical advantages over extraction
without laser tools and is associated with significant risks. (J Am Coll Cardiol 1999;33:
1671–6) © 1999 by the American College of Cardiology
Tools and techniques for the transvenous removal of cardiac
pacemaker leads have been demonstrated to be effective, but
are associated with a small but significant risk to the patient
(1). Fibrotic tissue develops over time and entraps the
implanted lead in the veins and in the cardiac chambers
(2,3). The existing extraction sheaths (Cook Vascular In-
corporated, Leechburg, Pennsylvania) are advanced over
leads to tear and peel away the encapsulating tissue. Excimer
laser generators produce pulsed ultraviolet light capable of
dissolving human tissue, a technique that has found appli-
cation in angioplasty (4). The excimer laser has also been
applied to pacemaker lead removal (5). The laser sheath
(The Spectranetics Corporation, Colorado Springs, Colo-
rado) fiberoptically delivers the laser energy to the distal end
of the sheath to release the lead from the encapsulating
fibrotic tissue, permitting the advancement of the sheath
without excess force or tearing of the tissues. To test the
safety and efficacy of the laser sheath, the Pacemaker Lead
Extraction with the Excimer Sheath (PLEXES) Trial was
conducted at multiple centers in the USA.
METHODS
The laser sheath, shown in Figure 1, replaces the inner
sheath of the Teflon telescoping sheath set. The 35-cm long
sheath consists of thin inner and outer polymer walls
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between which a single layer of optical fibers has been
spirally wrapped (6). At the distal tip of the sheath the fibers
present a single circumferential ring of light sandwiched
between the inner and outer walls of the tip. At the
proximal end of the sheath the fibers pass through a
connecting cable to the laser generator. The 12-F laser
sheath has an inner diameter of 8.4 F (2.8 mm) and an outer
diameter of 12.4 F (4.1 mm).
The CVX-300 Excimer XeCl Laser System (Spectranet-
ics Corporation, Colorado Springs, Colorado) emits 135-ns
pulses (308 nm wavelength) at a repetition rate of 25 to
40 Hz. The fluence (output energy per unit area of fiber) at
the distal tip of the device can be set to values between 30
and 60 mJ/mm2.
Extensive research has been reported on laser–tissue
interaction with this laser system (7–10). A combination of
photochemolysis and photothermal ablation causes the layer
of tissue immediately in contact with the device tip to
disintegrate into particles no larger than 5 mm in diameter.
Since the penetration depth of 308-nm light in vascular
tissue is approximately 100 mm, the laser light is completely
absorbed by the tissue immediately in front of the tip. This
produces a controlled and precise removal of only that
encapsulating fibrous tissue directly surrounding the lead
body (11).
Statistical methods. Case data were recorded on paper
forms, forwarded to the data coordination center and keyed
into a computer database (SAS/STAT, SAS Institute Inc,
Cary, North Carolina). Data from all centers were pooled
before analysis. Means of continuous variables were com-
pared by Student t test at 95% confidence. Differences in
dichotomous categorical variables were deemed significant if
the chi-square test yielded p , 0.05. Multivariate predictors
of nonlaser failure were selected from the list of univariate
predictors if the coefficients for a predictor were significant
at p , 0.05 in a multivariate logistic regression model built
using the model-building strategies of Hosmer and Leme-
show (12).
Trial protocol. Overall, 301 patients with 465 pacemaker
leads were prospectively randomized into the laser and
nonlaser groups after granting written informed consent.
Nine institutions in the U.S. contributed patients during the
period from November 1995 to October 1996, after human
ethics committee approval was received at each site.
Investigators were selected by their prior experience with
lead extraction and were required to visit an active site to
observe laser-assisted pacemaker lead removal. In addition,
the first two laser procedures at each new site were proctored
and not entered into the randomization. The training
protocol was an attempt to reduce the bias related to the
learning curve. Thereafter all patients who met the trial
criteria were randomized at each institution.
Patient inclusion criteria for the PLEXES study required
a lead with at least one year of implantation duration,
accessibility of the lead from the subclavian, internal or
external jugular or cephalic veins, informed consent, man-
datory or necessary indications for lead removal and avail-
ability of all necessary extraction equipment (13). Exclusion
criteria included the inability to use fluoroscopy, unavail-
ability of surgical backup, and a lead too large for the laser
sheath. A registry of the excluded patients was not main-
tained; however, failure to enroll an eligible patient was rare.
For both groups, the primary end point was complete
removal of the lead by the randomized therapy without the
development of a complication. The secondary end point
added subtotal lead removal by the randomized therapy
leaving behind only the electrode with or without a short
segment (,4 cm) of conductor coil.
A second analysis determined the clinical success rate per
patient instead of per lead; this “intention-to-treat” analysis
required complete or subtotal extraction of all targeted leads
by all techniques, laser, nonlaser and femoral tools, without
complications. The time required to remove each lead and
to remove all the targeted leads from each patient was
recorded. These definitions were chosen to conform to
published terminology (1).
Procedural failure for both the laser and nonlaser groups
was defined as: 1) failure to gain venous entry; 2) failure to
pass through a binding site, as evidenced by partial lead
deformation or destruction of the plastic or laser sheath; 3)
change to the transfemoral or transatrial or thoracotomy
approach; 4) failure to extract the lead, or 5) occurrence of
a complication. In the nonlaser group, the leads were
removed by standard lead extraction counterpressure and
countertraction techniques from the subclavian, jugular or
cephalic veins (14), under fluoroscopic guidance. This ap-
proach was used until the procedure yielded lead removal or
an objective measure of failure. If there was failure of the
Figure 1. The laser sheath is the tubular structure that passes over
the pacemaker lead. The inset demonstrates the wrapping of the
optical fibers that conduct pulsed ultraviolet light to the distal tip
as a ring of light. Also pictured is the modular connector, which
attaches to the excimer laser generator and transmits the light to
the tubular or working section of the sheath.
1672 Wilkoff et al. JACC Vol. 33, No. 6, 1999
PLEXES Results May 1999:1671–6
nonlaser approach, the investigator was free to choose any
alternative modality to complete the extraction procedure.
In the laser group, standard lead extraction techniques
were used with the exception that the laser sheath replaced
the inner telescoping extraction sheath. In a typical proce-
dure, a locking stylet was placed in the lead. A Teflon outer
sheath was preloaded over the laser sheath before the stylet
and lead were threaded through the assembly. The laser
sheath and outer sheath were passed over the lead body until
the first binding site was reached. Five-second bursts of
excimer laser energy combined with gentle advancement
pressure on the laser sheath and withdrawal traction on the
locking stylet ablated the tissue and enabled the sheaths to
advance to the next binding site. The CVX-300 was
adjusted to the maximal setting of fluence of 60 mJ/mm2
and a repetition rate of 40 pulses per second. The sheath
assembly was advanced over the lead until it was freed from
its attachments or until the sheath tip reached a point a few
millimeters from the heart wall. At this point, the outer
sheath was advanced, and countertraction was applied to
remove the lead.
Table 1 shows demographic information on the 301
patients enrolled in the randomized trial. No significant
differences were seen between the two groups in age,
gender, lead implantation duration or the lead’s character-
istics such as manufacturer, chamber location, insulation
type or polarity. Following the classification of Byrd et al.
(13), the indications for extraction were classified into two
categories: Mandatory or Necessary. Only 11.6% of patients
presented with Mandatory indications, primarily infection.
Table 1 shows that the most frequent Necessary indications
were lead replacement and pocket infection. Many patients
presented with more than one lead and several and overlap-
ping indications for removal.
A summary of the lead information shows that 1.54 6
0.68 leads were extracted per patient (Table 2). Slightly
more atrial leads were removed in a ratio of 1.1:1 compared
with ventricular leads. By far the most common lead model
extracted was the Telectronics (Telectronics Inc., Engle-
wood, Colorado) 330-801 Accufix atrial lead, which ac-
counted for 25% of all leads targeted for explantation in this
study. The leads were implanted for 67 6 44 months. There
were no statistically significant demographic differences
between the groups.
RESULTS
Extraction efficacy was significantly higher in patients ran-
domized to laser-assisted removal (p 5 0.001) (Table 3).
Complete or partial success was achieved for 97% of leads
randomized to laser versus 66% of leads in the nonlaser
group. Because the protocol allowed crossover to the laser if
deformation or partial destruction of the lead occurred, very
few procedures in the nonlaser group proceeded to the
secondary end point of partial extraction. Investigators
preferentially attempted to remove the entire lead with laser
Table 1. Patient Demographics and Extraction Indications
Nonlaser Laser p Value
Number of patients 148 153
Age (yr) 66 6 18 65 6 18 0.32
Female (%) 38% 33% 0.49
Mandatory indications 16 (11%) 19 (12%) 0.80
Septicemia 12 (8%) 15 (10%) 0.75
Endocarditis 4 (3% 7 (5%) 0.58
Lead migration 0 1 (1%) 0.99
Device interference 3 (2%) 0 0.23
No usable veins 1 (1%) 2 (1%) 0.98
Necessary indications 140 (95%) 147 (96%) 0.74
Pocket infection 38 (26%) 37 (24%) 0.87
Chronic draining sinus 9 (6%) 11 (7%) 0.88
Erosion 14 (9%) 12 (8%) 0.77
Vein thrombosis 5 (3%) 8 (5%) 0.61
Lead migration 2 (1%) 2 (1%) 0.64
Potential device interference 26 (18%) 13 (8%) 0.03
Tricuspid insufficiency 3 (2%) 4 (3%) 0.96
Lead replacement not Accufix 44 (30%) 53 (35%) 0.43
Lead replacement (Accufix) 57 (39%) 57 (37%) 0.92
Table 2. Lead Demographics
Nonlaser Laser p Value
Randomized leads 221 244
Leads/patient 1.49 6 0.69 1.59 6 0.67 0.10
Atrial 119 (54%) 125 (51%) 0.63
Ventricular 101 (46%) 118 (48%) 0.63
Coronary sinus 1 1 0.52
Fixation
Active 99 (45%) 106 (43%) 0.84
Passive 117 (53%) 134 (55%) 0.74
Other/unknown 5 (2%) 4 (2%) 0.88
Lead age (mo) 69 6 46 65 6 42 0.16
Table 3. Extraction Outcomes and Reasons for Failure
Nonlaser Laser p Value
Leads (n) 221 244
Complete extraction* 142 (64%) 230 (94%) , 0.001
Partial extraction 4 (1.8%) 6 (2.5%) 0.87
Failure* 75 (34%) 8 (3.3%) , 0.001
Failed venous entry 14 (6%) 0 , 0.001
Binding site impasse 42 (19%) 3 (1.2%) , 0.001
Lead disruption 14 (6%) 2 (0.8%) 0.003
Lead diameter 3 (1.4%) 0 0.21
Acute complication† 0 3 (1.2%) 0.28
Crossover to 12-F laser 72 (33%) — —
Crossover to 16-F laser 1 (0.5%) — —
Crossover to femoral 2 (0.9%) 5 (2.0%) 0.53
Clinical success of procedure
(patients)
142 of 148 145 of 153 0.83
(95.9%) (94.8%)
*p 5 0.001. †p 5 NS.
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assistance rather than leave a lead fragment behind. Of 72
leads crossed over to complete the extraction, 63 (88%) were
completely and three (4%) partially removed with the laser.
Multivariate predictors of failed extraction with the
nonlaser tools are: 1) lead manufacturer, 2) decreased
patient age, and 3) the extraction center. With respect to the
first predictor, the Telectronics 330-801 Accufix atrial lead
accounted for 57 (26%) of the nonlaser and 57 (23%) of laser
leads. This lead frequently met the failure criteria of
deformation or destruction of the lead, because the lead
body tends to pull apart between its electrodes during
explantation with the increased traction force required with
the nonlaser technique (14–16). Because the outer insula-
tion protects the patient from lacerations from the J wire,
partial destruction of the integrity of the lead was a
contributor to failed nonlaser attempts to remove these
leads. Of the 57 Accufix leads randomized to the nonlaser
approach, only 27 (47%) were removed successfully com-
pared with 96% of the laser randomized cases. In total, 86 of
87 (99%) Accufix leads treated with laser techniques as the
randomized or rescue technique were successfully removed.
In addition, all Accufix leads crossed over were completely
removed with the addition of laser tools.
Binding sites and dense fibrous tissue were found at all
locations from the venous entry site to the atrial or ventric-
ular destination. For successful laser cases a mean of 50 of
laser application (2,000 laser pulses) was used.
The elapsed time from the first application of sheaths to
the moment of explantation or failure is represented in
Table 4. The mean procedure duration for all randomized
and all successfully extracted cases was significantly shorter
for the laser group patients. However, a portion of the
nonlaser group patients (64%) had complete lead removal in
an average time of removal of 8.1 6 9.3 min. The other
third of the nonlaser patients required a second procedure,
and the total complete extraction time was 23.7 6 29.0 min.
In contrast, 94% of the laser group lead removals were
completely successful in 10.1 6 11.5 min. This increased
likelihood of success and shorter duration of the extraction
procedure was achieved despite the imposition of a 5-s
maximum laser burst length and a 10-s rest period between
laser bursts. Because the average case required 50 s of laser
treatment time, this produced 100 s of enforced rest periods
during an average laser-assisted lead removal.
Although there were no complications directly related to
the application of laser energy, there were significant com-
plications in five patients randomized to laser use and in two
patients randomized to nonlaser (p 5 NS). Three of these
patients, all randomized to laser, required procedural inter-
vention; one died after a cardiac tamponade. In the latter
patient, severe calcification was noted, which is a recognized
Table 4. Total Extraction Time: Intention to Treat Analysis
Extraction
Randomized
Nonlaser Randomized Laser Crossover to Laser
min n min n p min n
Complete 12.9 6 19.2 202 10.1 6 11.5 225 0.04 14.1 6 15.1 62
Partial 51.9 6 45.9 7 15.2 6 9.4 6 0.03 32.3 6 24.0 3
Failed 27.2 6 33.6 8 43.7 6 35.1 7 0.19 23.9 6 16.1 5
All leads 14.7 6 22.1 217 11.2 6 13.9 238 0.02 15.6 6 15.9 70
Table 5. Complications
Complication Randomization Result Description
Tamponade Laser Thoracotomy, death Laceration of the lateral right atrial wall produced cardiac tamponade and
consequent death. The atrial lead was tightly bound by densely
calcified scar tissue observed on chest radiography and fluroscopy.
Tamponade Laser Thoracotomy Laser removal of another lead was complete. Occurred during femoral
tool removal of a lead not eligible for randomization due to
preoperative retraction into the brachiocephalic vein.
Hemothorax Laser Chest tube Laser sheaths had been advanced to the distal electrode and had been
withdrawn. Polymer sheath advancement lacerated the SVC due to
inadequate tension on the lead during counterpressure.
Valve damage Laser Medical treatment Peripheral edema and severe tricuspid insufficiency were noted after a
difficult and failed extraction with the laser and other tools.
Thrombosis Nonlaser Anticoagulation SVC occlusion.
Thrombosis Laser Anticoagulation Arm edema.
Thrombosis Nonlaser Observation Arm edema.
SVC 5 superior vena cava.
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risk factor for lead extraction. In follow-up, two other
patients died from causes unrelated to the extraction pro-
cedure (Table 5).
DISCUSSION
The PLEXES study shows that the addition of the laser
sheath significantly improves the efficiency of transvenous
lead extraction. Telescoping stainless steel and polymer
sheaths require mechanical force to pass them over the leads
through dense fibrous tissue, allowing passage to a point
near the endocardial surface. With the laser sheath, the
pulsed ultraviolet light ablates the tissue, greatly reducing
the magnitude of force applied. Ideally, the laser sheath
minimizes the use of counterpressure. We attribute the differ-
ence in success rates to the cutting action of the laser sheath, a
feature that has been absent in other explantation tools.
Comparison with historical expectation. Extraction fail-
ure was defined differently in this trial than in previous
reports to highlight the impact of the laser sheaths on
extraction. Previously reported success rates of up to 95%
included the use of tools from the subclavian veins, femoral
veins and transatrial routes. The analogous rate of extraction
without the laser tools in prior studies (69% to 88%) would
include only those leads removed without the femoral and
transatrial techniques (1,14,17). In this study, success was
broadly defined as the inability to remove the lead from the
subclavian or cephalic vein approach even if the lead was
subsequently removed with femoral or transatrial tools. The
increased failure rate of 34% in the nonlaser group and
consequent crossover rate in this study suggest that there are
additional issues. In many cases, patients referred to the
PLEXES sites were preselected by their referring physician
because extraction was expected to be difficult. It should be
noted that only leads implanted .1 year were included in
the PLEXES study, whereas previous reports did not
impose this restriction.
The PLEXES study design allowed investigators to
declare failure in a nonlaser case when the lead began to
stretch or fall apart. Crossover to the 12-F laser sheath was
used in all but three of these patients. Crossover in the
opposite direction was meaningless, because the laser tech-
nique included the nonlaser tools and requires increased
traction forces on the leads. Most (88%) of these leads were
completely removed without changing to the femoral ap-
proach. Defining lead disruption as a failure end point
distinguishes this study from previous reports (1). Before
this experience, partial removal of a lead with nonlaser tools
was an acceptable outcome, occurring in over 7% of the
patients with implantation durations similar to the patients
in this study. It seems likely that in many of the crossover
cases partial success would have ensued with the nonlaser
approach. The complete success rate in either primary or
rescue laser-treated leads combined with the ease of removal
with this technique raised the expectations of the investi-
gators and biased toward earlier crossover. This bias was
further magnified by the higher incidence of fractured or
fragile leads, such as the Telectronics “Accufix” 330-801
atrial lead, in the PLEXES study vis-a`-vis the historical
database.
Another motivation for using the laser tool relates to the
predictability of the procedure. Not only were 94% of the
leads completely removed with this technique, the mean
procedure duration was 10.1 min. When the initial ap-
proach was nonlaser with the willingness to crossover to the
laser techniques, 95.9% of these patients achieved a clinical
success with an additional mean extraction time of
14.1 min. When the nonlaser technique was used 34% of
the leads required this additional intervention, which made
the total extraction time an average of 23.7 6 29.0 min. The
frequently time-consuming use of femoral extraction tools
was uncommon (,1% of leads) in the trial. The combina-
tion of improved complete success rates and reduced extrac-
tion times makes the laser approach attractive.
Management of complications. In this study, relatively
few patients presented with a “mandatory” indication for
lead removal. Lead replacement was the largest indication
by far, including replacement of leads under recall. Telec-
tronics 330-801 Accufix J leads contributed 114 of 211
(54%) of these leads. This implies that both patients and
their physicians believe that the benefits of extraction
presently outweigh the risks of leaving these leads in place.
Although complications occurred and were life-threatening,
the incidence of complications in the laser group remained
below 2%, comparable to previously published values (1).
Although statistically not significant, the larger number of
complications in laser group patients emphasizes the need
for extreme caution with this and all extraction approaches.
Further consideration of the risk versus benefit ratio will
require a much larger registration of cases as the tools and
level of experience improves.
One would anticipate that complications such as vascular
laceration, perforation, hemothorax, tamponade and death
might be present regardless of the percutaneous means of
extracting leads (1,14–16). Of the complications observed
with the laser-assisted technique, none was judged to be
secondary to the use of laser energy. However, experience
with the laser sheath indicates that additional precautions
should be taken. In some cases, the outer telescoping sheath
was retained in the vasculature when the laser sheath and
lead were removed together. If this technique is used, the
outer sheath should be positioned in the right atrium or
pulled back into the subclavian vein to avoid inadvertent
damage to the distal superior vena cava. Alternatively, the
extraction sheath should be removed after the introduction
of a J-tipped guide wire, and a long peel away introducer
that reaches the right atrial chamber should be used to
implant the replacement lead. These two techniques mini-
mize the possibility that the introduction of the new lead
would perforate the potentially extraction-weakened supe-
rior vena cava. This one potentially new, avoidable and
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life-threatening complication underscores the previously
identified need for aggressive monitoring and prompt and
competent surgical management.
Study limitations. As in any randomized trial with cross-
over, the mere existence of a crossover option raises the
question of bias. The protocol attempted to minimize bias
against the nonlaser group by providing “objective” mea-
sures of failure. However, even these measures contain some
degree of variability and subjectivity. For instance, each
investigator determined individually and in each patient’s
case how much force could be safely applied to a lead
without damaging it, thereby reaching a failure criterion.
This clearly was a source of site-to-site variability.
The lack of a crossover option would make the data more
convincing, but this trial without crossover may not have
served the best interests of the patients. Because most
crossover leads were extracted successfully by laser, it would
be difficult to argue that a femoral or transthoracic approach
would have served the patients better. Total study enroll-
ment was powered to show significance if laser achieved
94% success and nonlaser achieved 83% success, the best-
case historical benchmark. Thus, if crossover bias had not
been present and if nonlaser success had equaled the
literature value, laser would still have been shown to be
significantly more successful. It would certainly be true that
the mean nonlaser procedure time would have been even
longer.
Crossover from the laser group to a nonlaser modality was
specifically not included in the protocol. Because nearly all
standard extraction tools must be used in a laser case,
crossover to a nonlaser modality was practically indistin-
guishable from the laser modality. During the trial, it was
noted in some instances that the laser sheath did not
traverse the lead all the way to the tip, but the lead was
removed using polymer sheaths from the furthest advance-
ment of the laser sheath onward. Such an instance counted
as a laser group success, wherein the laser sheath and
polymer sheaths performed mutually adjunctive functions.
Conclusions. The results of the PLEXES Trial show that
the addition of the laser sheath to the standard tool set
provides an improved approach for completely removing
chronically implanted pacing leads. Although the possibility
for serious complications still exists in lead extraction, no
new safety issues were linked with the use of the device;
observed complications were not directly related to the laser.
Because the risks of lead extraction must always be weighed
against its benefits, the apparent effectiveness of the laser
sheath will certainly affect the standards used to evaluate
patients for lead extraction.
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